EUR 0.44
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 6.8 Million EUR | 6.14% |
2022 | 6.41 Million EUR | 120.57% |
2021 | 2.9 Million EUR | 43.84% |
2020 | 2.02 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 1.93 Million EUR | 0.0% |
2024 Q1 | 1.93 Million EUR | -71.58% |
2023 FY | 6.8 Million EUR | 6.14% |
2023 Q3 | 6.8 Million EUR | -18.58% |
2023 Q1 | 8.35 Million EUR | 30.35% |
2023 Q4 | 6.8 Million EUR | 0.0% |
2023 Q2 | 8.35 Million EUR | 0.01% |
2022 Q4 | 6.41 Million EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Nicox S.A. | - EUR | -Infinity% |
European Medical Solutions | 14.35 Million EUR | 52.598% |
argenx SE | 281.12 Million EUR | 97.579% |
BioSenic S.A. | - EUR | -Infinity% |
Celyad Oncology SA | 1.26 Million EUR | -440.159% |
Hyloris Pharmaceuticals SA | 1.00 EUR | -680599900.0% |
Onward Medical N.V. | 936 Thousand EUR | -627.137% |
Oxurion NV | 128 Thousand EUR | -5217.188% |
PHAXIAM Therapeutics S.A. | 671 Thousand EUR | -914.307% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 1.03 Billion EUR | 99.34% |